15:32 , Jun 8, 2018 |  BioCentury  |  Finance

Pfizer plugs back in

While Pfizer Inc. (NYSE:PFE) retreated from neuroscience R&D in January, the pharma hasn’t cut the cord yet. Ramped up allocations to neuroscience out of its latest $600 million venture investment give Pfizer the ability to...
03:02 , Feb 2, 2018 |  BC Innovations  |  Product R&D

It’s the assay...

Genentech and Xenon have reported that the key to finding a selective Nav1.7 blocker is devising a better screen, not using a bigger compound library. By retooling a commonly used assay, the partners identified a...
19:41 , Jun 2, 2017 |  BioCentury  |  Product Development

Ears wide open

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...
19:11 , May 8, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Addiction Rat studies suggest mGluR5 positive allosteric modulators (PAMs) or inhibitors of KCNN1 , KCNN2 and KCNN3 could help treat alcohol addiction. In a rat model of alcohol dependence, intraperitoneal (i.p.) or intracortical injection...
20:45 , Nov 1, 2016 |  BC Extra  |  Financial News

Acesion raises EUR 9.1M in series A

Cardiology company Acesion Pharma ApS (Copenhagen, Denmark) raised EUR 9.1 million ($10 million) in a series A round from existing investors Novo Seeds and the Wellcome Trust . CEO Frans Wuite told BioCentury the company...
07:00 , Jun 9, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Potassium channel Kv7.3 (KCNQ3)

Neurology INDICATION: Depression Mouse studies suggest promoting KCNQ3 expression or opening potassium channels could help treat major depressive disorder (MDD). In a mouse model of chronic depression, expression of KCNQ3 in ventral tegmental area dopaminergic...
07:00 , Mar 31, 2016 |  BC Innovations  |  Distillery Techniques

DISEASE MODELS

Disease models TECHNOLOGY: Transgenics and knockouts PTCHD1-knockout mice could be useful for screening therapies to help treat ADHD. Mice with PTCHD1 knocked out in the thalamic reticular nucleus recapitulated attention deficits and hyperactive behaviors seen...
07:00 , May 21, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: ATP-dependent potassium channel (KATP)

Neurology INDICATION: Alzheimer's disease (AD) Mouse studies suggest KATP agonists could help prevent AD in patients with Type II diabetes or other forms of hyperglycemia, which increases the risk of AD. In mouse models of...
07:00 , May 11, 2015 |  BioCentury  |  Product Development

Check your effectors

Phase Ib data reported last week for Kineta Inc .'s dalazatide gave the first clinical evidence that targeting Kv1.3 channels may quell an active autoimmune response by halting activation of effector memory T cells while...
07:00 , Mar 24, 2014 |  BioCentury  |  Finance

Quick turn

Quick turn In less than a year, Atlas has set up a potential exit for Ataxion Inc. via a $17 million tranched series A round that will fund the company through completion of a Phase...